tiprankstipranks
Defence Therapeutics (DTCFF)
OTHER OTC:DTCFF

Defence Therapeutics (DTCFF) Income Statement

9 Followers

Defence Therapeutics Income Statement

Last quarter (Q2 2024), Defence Therapeutics's total revenue was C$―, a decrease of ― from the same quarter last year. In Q2, Defence Therapeutics's net income was C$-8.32M. See Defence Therapeutics’s key income statements, including revenue, expenses, profit, and income.
Income Statement
TTM
Jun 23Jun 22Jun 21Jun 20
Total Revenue
----C$ 0.00
Cost of Revenue
-----
Gross Profit
-----
Operating Expense
C$ 13.39MC$ 6.55MC$ 7.32MC$ 2.86MC$ 673.18K
Operating Income
C$ -13.39MC$ -6.55MC$ -7.32MC$ -2.86MC$ -673.18K
Net Non Operating Interest Income Expense
C$ -339.31KC$ -256.12K---
Other Income Expense
-----
Pretax Income
C$ -13.69MC$ -6.87MC$ -7.34MC$ -2.86MC$ -673.18K
Tax Provision
C$ -105.00KC$ -105.00K---
Earnings From Equity Interest Net Of Tax
-----
Net Income Common Stockholders
C$ -13.59MC$ -6.76MC$ -7.34MC$ -2.86MC$ -673.18K
Basic EPS
C$ -0.31C$ -0.17C$ -0.20C$ -0.11C$ -0.02
Diluted EPS
C$ -0.31C$ -0.17C$ -0.20C$ -0.11C$ -0.02
Basic Average Shares
C$ 171.97MC$ 39.66MC$ 36.08MC$ 26.60MC$ 35.22M
Diluted Average Shares
C$ 171.97MC$ 39.66MC$ 36.08MC$ 26.60MC$ 35.22M
Dividend Per Share
-----
Total Operating Income As Reported
-----
Reported Normalized Basic E P S
-----
Reported Normalized Diluted E P S
-----
Rent Expense Supplemental
-----
Total Expenses
C$ 13.39MC$ 6.55MC$ 7.32MC$ -2.86MC$ 673.18K
Net Income From Continuing And Discontinued Operation
C$ -13.59MC$ -6.76MC$ -7.34MC$ -2.86MC$ -673.18K
Normalized Income
C$ -10.66MC$ -6.97MC$ -5.40MC$ -2.10MC$ -673.18K
Interest Expense
-----
EBIT
C$ -13.33MC$ -6.60MC$ -7.34MC$ -2.86MC$ -673.18K
EBITDA
C$ -13.31MC$ -6.59MC$ -7.34MC$ -2.86MC$ -673.18K
Currency in CAD

Defence Therapeutics Earnings and Revenue History

What's Included in PREMIUM?
Make informed decisions based on Top Analysts' activity
Know what industry insiders are buying
Get actionable alerts from top Wall Street Analysts
Find out before anyone else which stock is going to shoot up
Get powerful stock screeners & detailed portfolio analysis